Daré Bioscience (DARE)
Develops women's-health products spanning contraception, sexual health, menopause and vaginal health.
Something off on this page? Send us feedback.
Develops and commercializes women's-health products through direct sales, compounded prescriptions, partnerships and grant-funded development. Its portfolio spans marketed and clinical-stage products, while most therapeutic candidates remain dependent on trials, regulatory review and external commercialization.
Develops women's-health pharmaceuticals and delivery technologies across contraception, sexual health, vaginal health, menopause, fertility and infectious disease. The portfolio is assembled through licenses, acquisitions and collaborations, then advanced with external clinical and manufacturing providers.
XACIATO, a single-dose treatment for bacterial vaginosis, is FDA approved and commercialized by Organon. Flora Sync LF5 is sold directly through the DARE Health Hub, while DARE to PLAY Sildenafil Cream uses a cash-pay compounded-prescription model. Ovaprene, a hormone-free monthly intravaginal contraceptive candidate, remains in a pivotal trial.
Operates primarily in the United States, with an Australian subsidiary used for early clinical studies and certain worldwide rights under license. Progress depends on clinical and regulatory results, funding awards, outside service providers and commercial partners; Organon controls XACIATO marketing, distribution and sales.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 14, 2026 | UBS | Target | Target: — | Target: $1 |
| Sep 4, 2025 | Maxim Group | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.6M · Total debt $6.8M · Total assets $22.4M · Shareholders' equity −$560.1K
- Revenue
- $187.5K
- Operating income
- −$3.0M
- Net income
- −$3.0M
No dividends on record.
| Institutions | 8.51% | 1.30M shares | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Insiders | 1.09% | 167.4K shares | |
| 5 holders · as of Jul 2, 2026 | |||
| Other | 90.40% | 13.82M shares | |
| remainder | |||
15.29M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 4.19% | 640,877 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.92% | 140,093 | as of Jun 30, 2026 |
US Bancorp \DE\Institution | 0.79% | 120,920 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.60% | 91,269 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.42% | 64,248 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Organon
Nexplanon and NuvaRing contest monthly and long-acting contraception.
- CooperCompanies
Paragard is a major hormone-free contraception alternative.
- Pfizer
Established systemic and vaginal menopause-therapy alternatives.
- Perrigo
OTC Opill provides a low-friction contraceptive alternative.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Daré Bioscience | $0.8127 | −4.39% | $12.7M | — | — | 9.3 | — |
| Organon | $13.74 | +0.26% | $3.60B | 17.8 | 3.9 | 0.6 | +0.5% |
| CooperCompanies | $55.49 | +0.36% | $10.78B | 18.9 | 12.1 | 2.5 | +0.6% |
| Pfizer | $28.18 | +0.88% | $159.19B | 36.9 | 10.1 | 2.5 | +2.6% |
| Perrigo | $13.97 | −2.38% | $1.98B | — | 5.9 | 0.5 | −3.2% |
| Median | 18.9 | 8.0 | 1.5 | +0.5% |